Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
iCAD Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
ICAD
Nasdaq
3845
http://www.icadmed.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for iCAD Inc
iCAD Announces CFO Transition
- May 25th, 2022 12:01 pm
New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography
- May 18th, 2022 12:00 pm
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
- May 16th, 2022 5:20 pm
New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
- May 16th, 2022 12:00 pm
iCAD to Present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 17th, 2022
- May 12th, 2022 7:30 pm
Icad (ICAD) Reports Q1 Loss, Tops Revenue Estimates
- May 11th, 2022 10:05 pm
iCAD Reports Financial Results for First Quarter Ended March 31, 2022
- May 11th, 2022 8:07 pm
Here's Why We're Not Too Worried About iCAD's (NASDAQ:ICAD) Cash Burn Situation
- May 11th, 2022 7:46 pm
Pros Holdings (PRO) Reports Q1 Loss, Tops Revenue Estimates
- May 3rd, 2022 10:05 pm
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Clinical and IT Experts from Wake Radiology
- Apr 28th, 2022 12:00 pm
iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11
- Apr 27th, 2022 12:00 pm
iCAD Announces Significant Commercial Momentum for ProFound AI Among Customers Equipped with the Leading Provider of 3D Mammography Systems
- Apr 26th, 2022 12:00 pm
iCAD Announces Estimated Q1 Revenue and Upcoming Board and CFO Transitions
- Apr 21st, 2022 12:00 pm
iCAD Launches ProFound Insights, ProFound Impact Webinar Series on April 27
- Apr 19th, 2022 12:00 pm
iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment
- Apr 5th, 2022 12:00 pm
Investors in iCAD (NASDAQ:ICAD) have unfortunately lost 79% over the last year
- Mar 29th, 2022 3:46 pm
iCAD Highlights Breast Health AI Platform at the 2022 Healthcare Information and Management Systems Society (HIMSS) Meeting
- Mar 14th, 2022 12:00 pm
iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annual Conference
- Mar 10th, 2022 1:00 pm
iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference
- Mar 9th, 2022 4:21 pm
iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite
- Mar 2nd, 2022 1:00 pm
Scroll